Among other conditions, BlueRock Therapeutics’ portfolio centres around cellular therapies for heart failure, autoimmune graft-host disease, and Parkinson’s disease.

Chinese tech company Tencent has partnered with UK-based medical firm Medopad to develop an artificial intelligence (AI) system for remote monitoring of patients suffering from Parkinson’s disease.

The partners have also collaborated with Parkinson’s Center of Excellence at King’s College Hospital in London to support their project, reported the BBC.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Medopad develops mobile apps to monitor various conditions such as diabetes, cancer, heart disease and rare diseases.

The firm’s app for Parkinson’s is designed to offer a video test for fine hand movements such as opening and closing the fists, which are then digitally analysed. This will allow doctors to remotely examine the strength and movement tests that are commonly performed in person.

Under the new project, the partners aim to train new AI software to automatically score these tests. They worked together with King’s College Hospital to train the technology using existing videos of patients assessed by doctors.

“Our partnership with Tencent comes from a shared vision to change the future of healthcare as we know it.”

According to Bloomberg, the software can currently translate the tests’ video images from a patient’s smartphone into a graph, which can be used by doctors to assess the patient’s performance.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Furthermore, Tencent and Medopad hope to cut the time taken for such motor function evaluations from the current 30 minutes to three minutes.

Medopad founder and CEO Dan Vahdat said: “Our partnership with Tencent comes from a shared vision to change the future of healthcare as we know it.

“In combining Medopad’s medical expertise and Tencent’s technical capabilities, we hope to provide the technology needed to support clinicians to predict preventable complications for people with Parkinson’s disease.”

In January this year, Medopad signed a memorandum of understanding with Johns Hopkins University.

The deal provides the university with access to Medopad’s patient monitoring platform, AI and machine learning capabilities, which will be applied to clinical and public health projects.